Please assess the completion status of the following clinical trial:

Trial Title: Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Histologic proof of epithelial ovarian,fallopian or peritoneal carcinoma of the following histological types:serous, endometrioid, mucinous, clear cell, low differentiation.~2. Age 18 years or older~3. Patients should have received first-line platinum based chemotherapy~4. Documented CA125 progression according to GCIC criteria.~5. No evidence of measurable or evaluable disease.~6. Provision of written informed consent~7. ECOG PS 0-2~8. Life expectancy of greater than 12 weeks~9. WBC\>4000/μl, platelets \> 100,000/μl and a hemoglobin level \> 9.5 g/dl. Adequate baseline hepatic function, defined as a total bilirubin level \< 2 mg/dl, SGPT and SGOT \< 2.5 times the upper limits of normal. Creatinine \< 1.5 mg/dl or creatinine clearance \> 60 ml/min.~10. All females of childbearing potential must have a negative serum or urine pregnancy test obtained within 2 days prior to initiation of treatment and use effective contraception during the period of therapy.~11. At least one month from the last chemotherapy administration.~12. Provision of adequate paraffin-embedded tumor tissue for translational studies (optional).~Exclusion Criteria:~1. Other histological types (germ cell, granulose tumors etc)~2. History of atrial or ventricular arrhythmias and/or history of congestive heart failure, even if medically controlled. History of clinical and electrocardiographically documented myocardial infarction within the last 6 months from study entry~3. Any evidence of clinically active interstitial lung disease (patients with chronic stable radiographic changes who are asymptomatic need not be excluded)~4. Pre-existing motor or sensory neurotoxicity grade 2 according to the WHO criteria (intolerable paresthesia and/or marked motor loss or worse)~5. History of any treatment for CA125 relapse~6. Known, severe hypersensitivity to temsirolimus or any of the excipients of this product~7. Other coexisting malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ~8. Any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer therapy~9. As judged by the investigator, any evidence of severe or uncontrolled systemic disease (eg unstable or uncompensated respiratory, cardiac, hepatic or renal disease)~10. Alanine amino transferase (ALT) or aspartate amino transferase (AST) greater than 2.5 times the ULRR.~11. Active infection or evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the trial/ receive protocol treatment~12. Concomitant use of Cyp3 A inducers (phenytoin, carbamazepine, rifampicin, barbiturates or St John's Wort) should be avoided and as should treatment with strong CyP 3A inhibitors~13. Treatment with a non-approved or investigational drug within 30 days before Day 1 of trial treatment.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).